journal article·2023-02-22

Physical- and Chemical-Dually ROS-Responsive Nano-in-Gel Platforms with Sequential Release of OX40 Agonist and PD-1 Inhibitor for Augmented Combination Immunotherapy

Yu Fu, Yulan Huang, Pingrong Li, Luyao Wang, Zhongjie Tang, Xinlong Liu, Xufei Bian, Shuang Wu, Xiaoyou Wang, Biyue Zhu, Yang Yu, Jiayun Jiang, Chong Li

Nano Letters· Volume 23· Issue 4
Publisher page

Abstract

Combination immunotherapy synergizing the PD-1 blockade with OX40 agonism has become a research hotspot, due to its enormous potential to overcome the restricted clinical objective response suffered by monotherapy. Questions of timing and sequence have been important aspects of immunotherapies when considering immunologic mechanisms; however, most of the time the straightforward additive approach was taken. Herein, our work is the first to investigate an alternative timing of aOX40 and aPD-1 treatment in melanoma-bearing mice, and it demonstrates that sequential administration (aOX40 first, then aPD-1 following) provided superior antitumor benefits than concurrent treatment. Based on that, to further avoid the limits suffered by solution forms, we adopted pharmaceutical technologies to construct an in situ -formed physical- and chemical-dually ROS-responsive nano-in-gel platform to implement sequential and prolonged release of aPD-1 and aOX40. Equipped with these advantages, the as-prepared (aPD-1NCs&aOX40)@Gels elicited augmented combination immunity and achieved great eradication of both primary and distant melanoma tumors in vivo .
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical Research Institute, College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China

Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford OX1 2JD, U.K.

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Harvard University, Charlestown, Massachusetts 02138, United States

Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University/Army Medical University, Chongqing 400038, P.R. China

Funding

Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China · Natural Science Foundation of Chongqing, China · Doctoral Through Train Scientific Research Project of Chongqing · Sichuan Science and Technology Program · Innovative Research Group at Higher Educational Institutions in Chongqing

References (45)

Show source-provided references
1. 10.1038/s41467-020-17670-y10.1038/s41467-020-17670-y ↗
2. 10.1038/s41586-021-03752-410.1038/s41586-021-03752-4 ↗
3. 10.1021/acs.nanolett.2c0272410.1021/acs.nanolett.2c02724 ↗
4. 10.1038/d41586-020-01038-910.1038/d41586-020-01038-9 ↗
5. 10.1038/s41416-020-0738-510.1038/s41416-020-0738-5 ↗
6. 10.1021/acs.nanolett.2c0090710.1021/acs.nanolett.2c00907 ↗
7. 10.3389/fonc.2015.0003410.3389/fonc.2015.00034 ↗
8. 10.1056/NEJMoa191083610.1056/NEJMoa1910836 ↗
9. 10.1038/s41571-019-0218-010.1038/s41571-019-0218-0 ↗
10. 10.1056/NEJMoa170968410.1056/NEJMoa1709684 ↗
11. 10.1016/j.intimp.2022.10881310.1016/j.intimp.2022.108813 ↗
12. 10.1016/j.apsb.2019.08.01010.1016/j.apsb.2019.08.010 ↗
13. 10.1016/j.ejca.2015.08.02110.1016/j.ejca.2015.08.021 ↗
14. 10.1016/j.jconrel.2021.08.00810.1016/j.jconrel.2021.08.008 ↗
15. 10.1038/s41467-021-21383-110.1038/s41467-021-21383-1 ↗
16. 10.1053/j.gastro.2020.03.01810.1053/j.gastro.2020.03.018 ↗
17. 10.1371/journal.pone.008935010.1371/journal.pone.0089350 ↗
18. 10.1002/adma.20170609810.1002/adma.201706098 ↗
19. 10.1016/j.jhep.2019.02.01610.1016/j.jhep.2019.02.016 ↗
20. 10.1371/journal.pone.015716410.1371/journal.pone.0157164 ↗
21. 10.1007/s00262-015-1759-410.1007/s00262-015-1759-4 ↗
22. 10.1158/2326-6066.CIR-16-024910.1158/2326-6066.CIR-16-0249 ↗
23. 10.1158/1078-0432.CCR-16-267710.1158/1078-0432.CCR-16-2677 ↗
24. 10.1158/1078-0432.CCR-17-233210.1158/1078-0432.CCR-17-2332 ↗
25. 10.1016/j.jconrel.2021.01.01110.1016/j.jconrel.2021.01.011 ↗
26. 10.1021/acs.nanolett.9b0058410.1021/acs.nanolett.9b00584 ↗
27. 10.1038/nbt.418110.1038/nbt.4181 ↗
28. 10.1002/adma.20170014110.1002/adma.201700141 ↗
29. 10.1126/scitranslmed.aaw474410.1126/scitranslmed.aaw4744 ↗
30. 10.1016/j.jconrel.2020.04.01410.1016/j.jconrel.2020.04.014 ↗
31. 10.1021/acsami.0c1949210.1021/acsami.0c19492 ↗
32. 10.1038/s41551-017-0157-y10.1038/s41551-017-0157-y ↗
33. 10.1021/acsnano.7b0297010.1021/acsnano.7b02970 ↗
34. 10.1021/acsbiomaterials.0c0119010.1021/acsbiomaterials.0c01190 ↗
35. 10.1021/acs.biomac.9b0062810.1021/acs.biomac.9b00628 ↗
36. 10.1038/s41590-022-01170-w10.1038/s41590-022-01170-w ↗
37. 10.1016/j.cell.2019.03.00510.1016/j.cell.2019.03.005 ↗
38. 10.1038/s41467-021-22303-z10.1038/s41467-021-22303-z ↗
39. 10.1126/sciimmunol.aan815610.1126/sciimmunol.aan8156 ↗
40. 10.1126/sciimmunol.abi507210.1126/sciimmunol.abi5072 ↗
41. 10.1093/intimm/dxx07310.1093/intimm/dxx073 ↗
42. 10.1021/acs.nanolett.2c0199410.1021/acs.nanolett.2c01994 ↗
43. 10.1126/scitranslmed.abl364910.1126/scitranslmed.abl3649 ↗
44. 10.1126/sciadv.abn294110.1126/sciadv.abn2941 ↗
45. 10.1189/jlb.030719110.1189/jlb.0307191 ↗